
Inducare Pharmaceuticals And Research Foundation Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
- Paid Up Capital ₹ 5.31 Cr
- Company Age 6 Year, 9 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 15.78 Cr
- Satisfied Charges ₹ 4.06 Cr
- Revenue Growth %
- Ebitda
- Net Worth 46.30%
- Total Assets 104.16%
About Inducare Pharmaceuticals And Research Foundation
Inducare Pharmaceuticals And Research Foundation (IPARF) is a Private Not For Profit Company incorporated in India on 19 February 2019 (Six years 9 days old ). Its registered office is in Pune, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 5.31 Cr.
The company currently has active open charges totaling ₹15.78 Cr. The company has closed loans amounting to ₹4.06 Cr, as per Ministry of Corporate Affairs (MCA) records.
Tukaram Bhondave, Monali Rajurkar, Ramadas Kute, and One other member serve as directors at the Company.
Company Details
- Location
Pune, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U85300PN2019NPL182301
- Company No.
182301
- Company Classification
Private Not For Profit Company
- Incorporation Date
19 Feb 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Inducare Pharmaceuticals And Research Foundation?
Board Members (4)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Shantanu Joshi ![]() | Nominee Director | 26-Feb-2021 | Current |
Ramadas Kute ![]() | Director | 19-Feb-2019 | Current |
Tukaram Bhondave ![]() | Director | 03-Sep-2019 | Current |
Monali Rajurkar ![]() | Nominee Director | 26-Feb-2021 | Current |
Financial Performance of Inducare Pharmaceuticals And Research Foundation.
Inducare Pharmaceuticals And Research Foundation, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth Soared by an impressive increase of 46.3%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue | |||||||
Revenue from Operations | |||||||
Total Assets |
| ||||||
Profit or Loss | |||||||
Net Worth |
| ||||||
EBITDA |
What is the Ownership and Shareholding Structure of Inducare Pharmaceuticals And Research Foundation?
In 2023, Inducare Pharmaceuticals And Research Foundation had a promoter holding of 61.77% and a public holding of 38.23%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Related Corporates (Common Directorship)
- Inducare Pharma Private Limited
Monali Rajurkar and Ramadas Kute are mutual person
- Acuere Biosciences Private Limited
Shantanu Joshi is a mutual person
- Indumati Pharma Private Limited
Ramadas Kute is a mutual person
- Acuere Lifescience Foundation
Shantanu Joshi is a mutual person
Charges (Loans)
₹15.78 Cr
₹4.06 Cr
Charges Breakdown by Lending Institutions
- Others : 15.78 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
01 Nov 2023 | Others | ₹6.00 Cr | Open |
23 Feb 2023 | Others | ₹3.86 Cr | Open |
23 Feb 2023 | Others | ₹5.92 Cr | Open |
11 Jan 2022 | Others | ₹4.06 Cr | Satisfied |
How Many Employees Work at Inducare Pharmaceuticals And Research Foundation?
Unlock and access historical data on people associated with Inducare Pharmaceuticals And Research Foundation, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Inducare Pharmaceuticals And Research Foundation, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Inducare Pharmaceuticals And Research Foundation's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.